Follow the 케이바이오랩스 share price and the full management transaction log of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 케이바이오랩스 has recorded 50 insider filings. Market capitalisation: €23.1bn. The latest transaction was reported on 16 July 2026 (Other). Among the most active insiders: 미래아이앤지. Every trade is accessible without an account.
40
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
n/a
22 ops.
Sell Volume
Fundamental score
Ranked 21,222 of 29,062 companies
36.2
score / 100
Value
55
Quality
18
FCF yld35%
Earn yld-14%
EV/EBITDA·
ROE·
Gross mgn14%
Net mgn-3.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.